IASO Biotherapeutics recently announced the completion of $60 million in series B financing led by GL Ventures, which is a venture capital fund of Hillhouse Capital focusing on early-stage innovative companies. Biomedicine and medical devices are its key investment areas. This new funding will mainly go toward expanding the company’s product pipeline, promoting the progress of current projects (including regulatory applications and clinical trials in China and the United States), improving the technology of fully human antibody development platform, expanding cooperation with leading international research and development institutions, and accelerating the construction of commercial facilities.
September 10th,2019, IASO Biotherapeutics(IASO Bio), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, announced today that the Company has received an Investigational New Drug Application (IND) approval from the National Medical Products Administration (NMPA) for the treatment of relapsed refractory multiple myeloma (rr/mm) patients.
IASO Biotherapeutics (IASO Bio),one of the top biotechnology innovators, announced that potential best-in-class therapy back-to-back at two of the most prestigious clinical meetings in the worlds of hematology and oncology,the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago Illinois,May 31-June 4[Abstract#8013; Tuesday,June 4,CDT],and the 24th Congress of the European Hematological Society (EHA),June 13–16[Abstract#S827;Saturday,June 15,12:35 PM-12:45 PM CEST].